ReviewBreast cancer (Dove Medical Press)2020
Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data.
Review in Breast cancer (Dove Medical Press), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Artificial Intelligence and the Evolving Landscape of Immunopeptidomics.Proteomics. Clinical applications · 2025Review
- Amplifying Immune Responses: Microparticulate Vaccine Approach Against Breast Cancer.Breast cancer (Dove Medical Press) · 2024Article
- Novel HER-2 Targeted Therapies in Breast Cancer.Cancers · 2023Review
- Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment.Breast cancer research and treatment · 2023Article
- Immunological Landscape of HER-2 Positive Breast Cancer.Cancers · 2022Review
- Review
- Targeting HER2 in breast cancer: new drugs and paradigms on the horizon.Exploration of targeted anti-tumor therapy · 2021Review
- Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccine therapies for treatment and prevention of cancer have seen modest degrees of efficacy with wide variation related to the tumor type, vaccine type, adjuvants and clinical setting for their study. Over the course of the last two decades, various peptide vaccines for breast cancer have been studied. The current leading peptide vaccine for human application is a HER2-based vaccine known as Nelipepimut-S, which has demonstrated immune activity and promising clinical activity in some settings. This review covers the development of this newer peptide vaccine for both HER2 amplified and non-amplified breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.